Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Chenggong Rd., Neihu Dist, Taipei City 114, Taiwan.
BMC Cancer. 2022 Jul 14;22(1):768. doi: 10.1186/s12885-022-09852-2.
This study aimed to determine the pathological complete response (pCR), overall survival (OS), and disease-free survival (DFS) in patients with locally advanced esophageal squamous cell carcinoma (ESCC) using post-neoadjuvant chemoradiotherapy (nCRT) F-18-fluorodeoxyglucose (FDG).
This is a retrospective study of patients with locally advanced ESCC receiving nCRT and then esophagectomy between January 2011 and December 2018 in the Tri-Service General Hospital, Taipei, Taiwan. A total of 50 patients were enrolled in the study. Survival analysis was performed using the Kaplan-Meier method and Cox proportional hazards model. Univariate and multivariate analysis were used to determine the independent prognostic factors.
Fifty patients were enrolled in the study, and 18 had pathological complete response. Post-nCRT SUVmax ≥ 3 is a poor prognostic factor associated with overall survival (HR: 3.665, P = 0.013) and disease-free survival (HR: 3.417, P = 0.011). Poor prognosis was found in the non-pCR plus post-nCRT SUVmax ≥ 3 group compared with pCR plus post-nCRT SUVmax < 3 group.
SUVmax ≥ 3 is a poor prognostic factor in esophageal squamous cell carcinoma after trimodality treatment, even in patients having pathological complete response.
本研究旨在通过后辅助放化疗（nCRT）氟代脱氧葡萄糖（FDG）评估局部晚期食管鳞状细胞癌（ESCC）患者的病理完全缓解（pCR）、总生存（OS）和无病生存（DFS）。
这是一项回顾性研究，纳入了 2011 年 1 月至 2018 年 12 月在台湾三军总医院接受 nCRT 后行食管切除术的局部晚期 ESCC 患者。共纳入 50 例患者。采用 Kaplan-Meier 法和 Cox 比例风险模型进行生存分析。采用单因素和多因素分析确定独立的预后因素。
共纳入 50 例患者，18 例患者达到病理完全缓解。后 nCRT SUVmax≥3 是与总生存（HR：3.665，P=0.013）和无病生存（HR：3.417，P=0.011）相关的不良预后因素。非 pCR 加后 nCRT SUVmax≥3 组的预后较差，与 pCR 加后 nCRT SUVmax<3 组相比。
SUVmax≥3 是食管鳞状细胞癌三模态治疗后不良的预后因素，即使在病理完全缓解的患者中也是如此。
